Genetic Analysis AS Logo

Genetic Analysis AS

Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.

GEAN | SPGR

Overview

Corporate Details

ISIN(s):
NO0010692130 (+2 more)
LEI:
5493004G3I23R6STCD61
Country:
Norway
Address:
Ulvenveien 80B, 0581 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genetic Analysis AS is a research-driven diagnostics company specializing in the human microbiome market. The company develops and commercializes diagnostic solutions based on its proprietary GA-map® platform, a standardized technology for characterizing the microbiome. Its flagship product is the GA-map® Dysbiosis Test Lx, a CE-marked in-vitro diagnostic test used to identify and characterize gut bacterial imbalances (dysbiosis) in patients with conditions such as IBS and IBD. Genetic Analysis serves laboratory diagnostics, clinical research, and pharmaceutical clients, offering tools for routine testing and the co-development of companion diagnostics to support targeted drug therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genetic Analysis AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genetic Analysis AS

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genetic Analysis AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CureVac N.V. Logo
Pioneering mRNA technology for prophylactic vaccines and novel cancer immunotherapies.
United States of America CVAC
CURIS INC Logo
Biotech developing innovative cancer therapeutics for hematologic malignancies.
United States of America CRIS
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
CYBIN INC. Logo
A clinical-stage firm engineering novel psychedelic drugs for depression and anxiety.
United States of America CYBN
Cyclerion Therapeutics, Inc. Logo
Developing personalized therapy for TRD with a biofeedback device and anesthetics.
United States of America CYCN
Cyfuse Biomedical K.K. Logo Japan 4892
CYTOKINETICS INC Logo
Late-stage biopharma developing muscle-modulating drugs for heart and neuromuscular diseases.
United States of America CYTK
CytoMed Therapeutics Ltd Logo
Develops off-the-shelf cell immunotherapies using γδ T cells & NK cells for cancer treatment.
United States of America GDTC
CytomX Therapeutics, Inc. Logo
Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.
United States of America CTMX
Daebonglsco.,Ltd Logo
Develops raw materials and APIs for the personal care, pharmaceutical, and food industries.
South Korea 078140

Talk to a Data Expert

Have a question? We'll get back to you promptly.